Literature DB >> 12493144

Is there a role for aggressive surgical cytoreduction in patients with known metastatic cancer?

Maurie Markman.   

Abstract

Entities:  

Mesh:

Year:  2003        PMID: 12493144     DOI: 10.1007/s11912-003-0078-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  5 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  A critique of surgical cytoreduction in advanced ovarian cancer.

Authors:  A L Covens
Journal:  Gynecol Oncol       Date:  2000-09       Impact factor: 5.482

3.  Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.

Authors:  S M Eisenkop; R L Friedman; H J Wang
Journal:  Gynecol Oncol       Date:  1998-05       Impact factor: 5.482

4.  The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.

Authors:  M E van der Burg; M van Lent; M Buyse; A Kobierska; N Colombo; G Favalli; A J Lacave; M Nardi; J Renard; S Pecorelli
Journal:  N Engl J Med       Date:  1995-03-09       Impact factor: 91.245

5.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.